Study identifier:D1710C00010
ClinicalTrials.gov identifier:NCT00711074
EudraCT identifier:N/A
CTIS identifier:N/A
An Open-Label, Phase I Study to Assess the Excretion of Radioactivity, Metabolic Profiles and Pharmacokinetics following a Single Oral Dose of [14C]AZD5672 in Healthy Male Volunteers
Rheumatoid Arthritis
Phase 1
Yes
AZD5672
Male
4
Interventional
50 Years +
Allocation: N/A 
Endpoint Classification: Pharmacokinetics Study 
Intervention Model: Single Group Assignment 
Masking: Open Label 
Primary Purpose: Basic Science 
Verified 01 May 2025 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
| Arms | Assigned Interventions | 
|---|---|
| Experimental: 1 | Drug: AZD5672  single dose 200mg aqueous solution |